Background: The Trifecta valve (St Jude Medical, Inc, St Paul, Minn) was approved for commercial use by the US Food and Drug Administration in 2011. Several isolated cases have been reported since then, describing early structural valve deterioration. We report a case series of 8 Trifecta valve failures, describing patients' clinical substrate and management, and the pathologic characteristics of the explanted valves.
Results: Five patients underwent surgical aortic valve replacement, 2 patients received valve-in-valve transcatheter aortic valve replacement, and 1 patient died of cardiogenic shock before reintervention. The most common pathologic finding in the explanted valves was a tan-yellow fibrofatty circumferential pannus adherent to the inflow portion of the Trifecta valve.
Conclusions: Our findings provide further insights into the pathologic mechanisms leading to early Trifecta valve failure. In addition to tear of the noncoronary cusp of the Trifecta prosthesis described as the most common mechanism in the literature for its failure, circumferential pannus formation composed of fibrofatty tissue in the inflow portion and leaflet calcification concentrated around the posts in the outflow portion are important mechanisms contributing toward early Trifecta valve failure. (J Thorac Cardiovasc Surg 2017;154:1235-40)
Explanted Trifecta valve with structural degeneration in inflow and outflow portions.
Central Message
The Trifecta valve design provides a theoretic advantage for a better hemodynamic profile. However, early pannus formation and leaflet calcification may contribute toward early valve failure in a ''real-world'' experience.
Perspective
Early pannus formation in the inflow portion resulting in a decrease in the effective orifice area and leaflet calcification concentrated around the posts in the outflow portion of the Trifecta valves causing restricted leaflet mobility or prosthetic regurgitation are important mechanisms contributing toward early Trifecta valve failure.
See Editorial Commentaries pages 1241 and 1243.
Trifecta stented bioprosthetic valves (St Jude Medical, Inc, St Paul, Minn) were approved by the US Food and Drug Administration for commercial use in 2011. 1 The Trifecta valve is composed of a titanium framework covered with porcine pericardium. The valve leaflets are made from bovine pericardium. Porcine and bovine tissue are preserved and cross-linked using glutaraldehyde, and the valve is sterilized with formaldehyde and ethanol. Additional processing is done with an ethanolbased anticalcification agent. The supra-annular design and external wrap of the valve leverage a theoretic advantage to facilitate deployment in subjects with smaller aortic roots. Midterm 6-year follow-up results from the premarket approval study in 710 eligible patients have shown that freedom from reoperation was 99.4%, 98.6%, and 96.0% at 1 year, 3 years, and 6 years postimplant, respectively.
2 At our tertiary care referral teaching hospital, we have recently encountered a cluster of early Trifecta valve failure cases. This article discusses the clinical substrate and management of these cases and the pathologic characteristics of the explanted Trifecta valves.
CASE REPORTS Baseline Characteristics
We encountered 11 Trifecta valve failures in 10 patients. Of these patients, 3 had prosthetic valve endocarditis and have been excluded from this case series. The final analysis includes 8 Trifecta valve failures in 7 patients. The mean age of patients at the time of presentation was 68 AE 11 years. Six valve failures occurred in women, and 2 failures occurred in men. Five patients were Caucasian, 1 was African American, and 1 was Hispanic. Failure of a 19-mm Trifecta valve occurred in 2 patients, failure of a 21-mm Trifecta valve occurred in 3 patients, failure of a 23-mm Trifecta valve occurred in 1 patient, and failure of a 25-mm Trifecta valve occurred in 2 patients. Valve durability among these patients ranged from 3 months to 5 years, with a mean duration of 32 AE 21 months. Heart failure exacerbation was the most common manifestation with New York Heart Association class III symptoms. All 7 patients had underlying hypertension, and coronary atherosclerosis was present in 3 patients. Other comorbidities included asthma (n ¼ 1), chronic obstructive pulmonary disease (n ¼ 1), cirrhosis (n ¼ 1), diabetes mellitus (n ¼ 1), end-stage renal disease (n ¼ 1), hyperlipidemia (n ¼ 4), and history of tobacco use (n ¼ 3). Two patients had native bicuspid valves, and 2 patients had concomitant coronary artery bypass graft surgery at the time of first Trifecta valve replacement (Table 1) . Five patients received antiplatelet therapy with aspirin after Trifecta valve implantation; 1 patient received anticoagulant therapy with non-vitamin K oral anticoagulant apixaban (for thromboembolism prophylaxis in atrial fibrillation).
Echocardiographic Findings
The mode of presentation was prosthetic valve stenosis in 2 patients (1 with a 19-mm valve and 1 with a 21-mm valve), severe aortic regurgitation in 4 patients (1 with a 21-mm valve, 1 with a 23-mm valve, and 2 with 25-mm (Table 1) .
Management
The mean Society of Thoracic Surgeons risk score for perioperative mortality at the time of reintervention was 9.7% AE 8.1%. Five valve failures underwent redo surgical aortic valve replacement with a medium-sized Perceval (Sorin, Saluggia, Italy) sutureless aortic valve (n ¼ 2) (Video 1), a 21-mm Trifecta valve (n ¼ 1), a 25-mm Trifecta valve (n ¼ 1), and a 29-mm St Jude mechanical valve (n ¼ 1). Two patients had a valve-in-valve transcatheter aortic valve replacement with a 23-mm and a 26-mm CoreValve Evolut R (Medtronic, Inc, Minneapolis, Minn). One patient died of cardiogenic shock before reintervention (Table 2) .
Pathologic Findings
The predominant pathologic findings from the explanted valves were (1) the presence of a circumferential, homogenous, tan-yellow, fibrofatty tissue adherent to the inflow portion of the Trifecta valve (Figure 1, A) and (2) leaflet calcification concentrated around the posts in the outflow portion of the Trifecta valve (Figure 1 , B, and C). These findings were present in early structural valve deterioration manifesting as prosthetic stenosis, regurgitation, or mixed valve disease (Table 2) .
DISCUSSION
We report a cluster of early Trifecta valve failure cases encountered at our tertiary care referral teaching hospital. Five failures occurred in 19-and 21-mm valves, and 3 failures occurred in 23-and 25-mm valves. All 8 cases presented with symptoms of heart failure exacerbation with New York Heart Association class III symptoms. All valves were implanted in a supra-annular fashion using interrupted pledgeted sutures on the inflow aspect of the annulus. None of the cases of Trifecta valve implantation were performed using a continuous suturing technique. Only 1 of the 7 patients reported in this case series had end-stage renal disease.
The predominant echocardiographic lesion was prosthetic valve regurgitation, and the majority of cases were treated with repeat surgical aortic valve replacement. The hallmark pathologic findings in all of the explanted valves were the presence of a circumferential, homogeneous, tan-yellow, fibrofatty membrane adherent to the inflow portion of the Trifecta valves (Figure 1, A) and leaflet calcification concentrated around the posts in the outflow portion of the Trifecta valves (Figure 1 , B, and C), leading to restricted leaflet mobility manifesting as prosthetic aortic stenosis or regurgitation. In the recently published midterm 6-year outcomes of the 710 Trifecta valves that were implanted in patients between 2007 and 2009 during the premarket approval phase, 18 valves were explanted. 2 Of these 18 valves, 11 were explanted because of structural valve degeneration due to calcification or fibrous thickening (n ¼ 10) or noncalcified leaflet tear (n ¼ 1). 2 The majority of cases of structural valve deterioration in the premarket approval phase study occurred in the 23-mm and 25-mm Trifecta valves, in contrast to the current series in which most failures occurred with smaller valve sizes. 2 In the isolated cases of early Trifecta valve failure reported in the literature (n ¼ 8), the most common lesion causing prosthetic dysfunction was aortic regurgitation due to leaflet tear involving the noncoronary cusp (Table 3) . [3] [4] [5] [6] [7] [8] [9] Most cases also involved Trifecta valves of 23-mm and 25-mm sizes (Table 3 and Figure 1, D) .
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The design of the Trifecta valve provides a theoretic advantage for a better hemodynamic profile because the valve leaflets are externally mounted on a thin flexible titanium stent with no alignment stitch used on top of the leaflets, a design characteristic that has been implicated as the plausible cause for early valve failure in earlier iterations of pericardial tissue valves. 10 The most common cause of structural valve deterioration in the premarket approval phase study was fibrous thickening or calcific leaflet degeneration. 2 In the cluster of cases that we have reported, the most common cause of early valve failure was excessive pannus formation in the inflow portion, plausibly due to an inflammatory reaction to the porcine pericardium covering the framework and leaflet calcification concentrated around the posts in the outflow portion of the Trifecta valve, inhibiting leaflet mobility leading to prosthetic aortic stenosis or regurgitation. Pannus formation may contribute to leaflet mobility restriction per se or incite a biological reaction progressing to leaflet thrombosis, eventually causing leaflet degeneration in the form of fibrosis or calcification. 11 Most cases of Trifecta valve failure in the literature, similar to our experience, were managed by repeat surgical aortic valve replacement. However, valve-in-valve transcatheter aortic valve replacement is a feasible approach that can be deployed in managing this patient subset, although long-term efficacy data with regard to this approach are currently lacking. [6] [7] [8] Although early degeneration in our case series may be due to the manufacturing defect tracked to a specific lot number, random serial number distribution across different valve sizes ( 
CONCLUSIONS
The midterm 6-year follow-up results from the premarket approval phase study on 710 patients has demonstrated a 96.0% reoperation-free rate after Trifecta valve replacement. 2 We have encountered a cluster of early Trifecta valve failure cases in a ''real-world'' experience in a highvolume (692 Trifecta valve implants from June 2011 to November 2016) tertiary care referral teaching hospital. The most common cause of early valve failure in these cases was excessive pannus formation in the inflow portion of the Trifecta valve. More studies documenting ''real-world'' long-term follow-up of Trifecta valves are required to establish their durability and long-term efficacy.
